Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 29, 2026, 9:54 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1777–1800 of 2,345 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Pharmacokinetics and Pharmacodynamics Clear all

Conditions: Healthy Volunteer
Interventions: Subcutaneous RB006 0.5 mg/kg, Subcutaneous RB006 1.0 mg/kg, Subcutaneous RB006 3.0 mg/kg, Subcutaneous RB006 2.0 mg, Placebo; Drug
Lead sponsor: Regado Biosciences, Inc.; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 36 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Cystic Fibrosis
Interventions: Ivacaftor; Drug
Lead sponsor: Vertex Pharmaceuticals Incorporated; Industry
Eligibility: 2 Years to 5 Years
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 16
States / cities: Birmingham, Alabama • Aurora, Colorado • Atlanta, Georgia + 13 more

Conditions: Diabetes Mellitus, Type 2
Interventions: Placebo, Metformin, DA-1241; Drug
Lead sponsor: Dong-A ST Co., Ltd.; Industry
Eligibility: 18 Years to 55 Years · Male only
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Neovascular Age-related Macular Degeneration
Interventions: Placebo, LFG316; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 55 Years to 90 Years
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 3
States / cities: Phoenix, Arizona • Winter Haven, Florida • Cleveland, Ohio

Conditions: RAS Mutation, NF1 Mutation, RAF Mutation, Advanced Solid Tumors
Interventions: PAS-004 Capsules, PAS-004 Tablets; Drug
Lead sponsor: Pasithea Therapeutics Corp.; Industry
Eligibility: 18 Years and older
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 4
States / cities: Austin, Texas • Irving, Texas • San Antonio, Texas + 1 more

Conditions: Thrombin Inhibition
Interventions: AZD8165; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 45 Years · Male only
Enrollment: 9 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: Non-Small Cell Lung Cancer
Interventions: Avelumab, PF-06463922, Crizotinib; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 43 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2022
U.S. locations: 7
States / cities: Atlanta, Georgia • Boston, Massachusetts • Nashville, Tennessee

Conditions: Pediatric Obesity, Childhood Obesity
Interventions: Placebo, VI-0521 Mid Dose, VI-0521 Top Dose; Drug
Lead sponsor: VIVUS LLC; Industry
Eligibility: 12 Years to 17 Years
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016
U.S. locations: 4
States / cities: Baton Rouge, Louisiana • Marrero, Louisiana • Cincinnati, Ohio + 1 more

Conditions: Pulmonary Arterial Hypertension
Interventions: RVT-1201, Placebo; Drug
Lead sponsor: Altavant Sciences GmbH; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 20
States / cities: Phoenix, Arizona • Sacramento, California • Santa Barbara, California + 17 more

Conditions: Type2 Diabetes Mellitus
Interventions: Bexagliflozin, Exenatide Injection; Drug
Lead sponsor: Theracos; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017
U.S. locations: 1
States / cities: Evansville, Indiana

Conditions: Alzheimer's Disease
Interventions: Bryostatin for Injection, Placebo; Drug
Lead sponsor: Blanchette Rockefeller Neurosciences Insitute; Other
Eligibility: 50 Years and older
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008
U.S. locations: 1
States / cities: Morgantown, West Virginia

Conditions: Methamphetamine Metabolism, CYP2D6 Genotype
Interventions: A single oral 5 mg of duterium labeled methamphetamine; Drug
Lead sponsor: California Pacific Medical Center Research Institute; Other
Eligibility: 18 Years to 55 Years
Healthy volunteers: Accepts healthy volunteers
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Leukemia, Myeloid, Neoplasm Metastasis, Leukemia, Lymphoid, Prostate Cancer
Interventions: Not listed
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: Up to 100 Years
Enrollment: 2,579 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2020
U.S. locations: 15
States / cities: Washington D.C., District of Columbia • Tampa, Florida • Chicago, Illinois + 9 more

Conditions: Hepatic Impairment
Interventions: Olpasiran; Drug
Lead sponsor: Amgen; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 25 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 3
States / cities: Rialto, California • Orlando, Florida • San Antonio, Texas

Conditions: Diabetic Retinopathy
Interventions: BI 1467335, Placebo; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 79 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 16
States / cities: Dothan, Alabama • Phoenix, Arizona • Beverly Hills, California + 13 more

Conditions: Prion Disease
Interventions: PrP-siRNA; Drug
Lead sponsor: Broad Institute of MIT and Harvard; Other
Eligibility: 18 Years and older
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 5
States / cities: Boston, Massachusetts • Rochester, Minnesota • New York, New York + 2 more

Conditions: Congenital Adrenal Hyperplasia
Interventions: NBI-77860; Drug
Lead sponsor: Neurocrine Biosciences; Industry
Eligibility: 12 Years to 18 Years · Female only
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015
U.S. locations: 2
States / cities: Ann Arbor, Michigan • Seattle, Washington

Conditions: Obesity, Overweight
Interventions: LY4329090, Placebo; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 184 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2027
U.S. locations: 2
States / cities: Daytona Beach, Florida • Dallas, Texas

Conditions: Pulmonary Hypertension, Heart Failure With Preserved Ejection Fraction
Interventions: HS235, Placebo; Biological · Other
Lead sponsor: 35Pharma Inc., a GSK company; Industry
Eligibility: 18 Years and older
Enrollment: 126 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 2
States / cities: Kansas City, Missouri • Greenville, South Carolina

Conditions: Diabetes Mellitus, Type 2, Hypertension
Interventions: IW-1973, Placebo; Drug
Lead sponsor: Cyclerion Therapeutics; Industry
Eligibility: 30 Years to 75 Years
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017
U.S. locations: 1
States / cities: Chula Vista, California

Conditions: Hepatitis C
Interventions: BI 201335; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years to 64 Years
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012
U.S. locations: 3
States / cities: Atlanta, Georgia • Overland Park, Kansas • Salt Lake City, Utah

Conditions: Healthy Volunteers, Propionic Acidemia, Methylmalonic Acidemia, Organic Acidemia
Interventions: BBP-671, Placebo; Drug
Lead sponsor: CoA Therapeutics, Inc., a BridgeBio company; Industry
Eligibility: 15 Years to 55 Years
Enrollment: 79 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2023
U.S. locations: 3
States / cities: Topeka, Indiana • Pittsburgh, Pennsylvania • Austin, Texas

Conditions: Part 1 - Healthy Volunteers, Part 2 - Patients With Hypertension
Interventions: LFF269, Placebo to LFF269; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 93 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Alzheimer's Disease
Interventions: E2609, Placebo for E2609; Drug
Lead sponsor: Eisai Inc.; Industry
Eligibility: 50 Years to 85 Years
Enrollment: 65 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 2
States / cities: Glendale, California • Baltimore, Maryland

Search by objective public record fields.

Safety, Tolerability and PK/PD of RB006 in a Healthy Volunteer SAD

Study of Ivacaftor in Cystic Fibrosis Subjects 2 Through 5 Years of Age With a CFTR Gating Mutation

A Study To Evaluate The Safety,Tolerability, PK and PD Of DA-1241 In Healthy Male Subjects

Safety and Tolerability of Intravenous LFG316 in Wet Age-related Macular Degeneration (AMD).

PAS-004 in Patients With Advanced Solid Tumors

Oral AZD8165 After Single Oral Ascending Doses in Healthy Male Subjects

Study to Evaluate Safety, Efficacy, Pharmacokinetics And Pharmacodynamics Of Avelumab In Combination With Either Crizotinib Or PF-06463922 In Patients With NSCLC. (Javelin Lung 101)

A Pharmacokinetic Study Comparing VI-0521 With Placebo in Obese Adolescents

A Study of RVT-1201 in Patients With Pulmonary Arterial Hypertension (ELEVATE 1)

Bexagliflozin Drug/Drug Interaction Study With Exenatide Injection

Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics Study of Bryostatin 1 in Patients With Alzheimer's Disease

The Impact of Genetic Variation in CYP2D6 on the Pharmacokinetics and Pharmacodynamics of Methamphetamine

Analyses of Human Samples Collected in Clinical Trials

A Study to Evaluate the Pharmacokinetics, Safety, and Pharmacodynamics of Olpasiran in Participants With Various Degrees of Hepatic Impairment

A Study That Tests BI 1467335 in Patients With Diabetic Eye Disease (Diabetic Retinopathy). It Looks at the Way BI 1467335 is Taken up, the Effects it Has, and How Well it is Tolerated.

PrP-targeting siRNA Safety & Mechanism Study

Safety, Pharmacokinetics and Pharmacodynamics of NBI-77860 in Adolescent Females With Congenital Adrenal Hyperplasia

A Study of LY4329090 in Participants With Obesity or Overweight Who Are Otherwise Healthy

HS235 Study in Overweight and Obese Participants With Combined Pre and Post-Capillary Pulmonary Hypertension Due to Heart Failure With Preserved Ejection Fraction

Trial of IW-1973, A Stimulator of Soluble Guanylate Cyclase (sGC) in Patients With Stable Type 2 Diabetes and Hypertension

Drug Interaction Study With BI 201335 and Methadone or Buprenorphine/Naloxone

A First in Human, Dose Escalation Study to Evaluate the Safety and Tolerability of BBP-671 in Healthy Volunteers and Patients With Propionic Acidemia or Methylmalonic Acidemia

To Evaluate Pharmacokinetics of LFF269 in Healthy Volunteers and Patients With Hypertension

Evaluation of E2609 in Subjects With Mild Cognitive Impairment or Mild Dementia Due to Alzheimer's Disease (Study: E2609-A001-101 Amendment 02)